Oncolytic Vaccinia Virus-Mediated Antitumor Effect and Cell Proliferation Were Promoted in PTC by Regulating circRNA_103598/miR-23a-3p/IL-6 Axis

This article was published in the following Dove Press journal:
Cancer Management and Research

Shuilong Zhang¹
Qiang Wang¹
Dewei Li¹
Bo Huang²
Xia Hou³
Dongliang Wang¹
Zhifu Xiao¹
Hongjing Meng¹
Yuhang Zhang¹
Lingxiang Dong¹

¹Department of Thyroid Surgery, Shanxi Provincial People's Hospital, Taiyuan, People's Republic of China; ²Department of Gastrointestinal Pancreas, Hernia and Abdominal Wall Surgery, Shanxi Provincial People's Hospital, Taiyuan, People's Republic of China; ³Department of Chest Radiotherapy, Tumor Hospital of Shanxi Province, Taiyuan, People's Republic of China

Background: Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy, and cases have been rising steadily worldwide in the past few decades. Despite great progress having been made in surgery and chemotherapy for PTC, the survival rate of PTC patients has not increased significantly. Therefore, there is an urgent need to explore novel treatment strategies.

Materials and Methods: The levels of circRNA_103598, miR-23a-3p and IL-6 mRNA in PTC tissues and cells were examined by qRT-PCR assay. Cell proliferation and IC₅₀ values of oncolytic vaccinia virus (OVV) were detected by CCK-8 assay. A dual-luciferase reporter assay was performed to detect the relationships among circRNA_103598, miR-23a-3p and IL-6. ELISA was carried out to detect the expression of IL-6.

Results: We found that circRNA_103598 was increased in PTC tissues and cell lines and acted as a sponge for miR-23a-3p. Moreover, knockdown of miR-23a-3p suppressed the OVV-mediated antitumor effect and cell proliferation in PTC. In addition, we revealed that circRNA_103598 bound to miR-23a-3p as a sponge to promote IL-6 expression.

Conclusion: Our study first revealed the high expression and oncogenic function of circRNA_103598 in PTC cells. Then, circRNA_103598 sponged miR-23a-3p to upregulate IL-6 expression, with the resulted that cell proliferation was promoted and the OVV-mediated antitumor effect was enhanced by strengthening the viral replication, providing new insights into future therapy for PTC.

Keywords: OVV, cell proliferation, circRNA_103598, miR-23a-3p, IL-6, PTC

Introduction

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy, and cases have been rising steadily worldwide in the past few decades.¹ Despite great progress having been made in surgery and chemotherapy for PTC, the survival rate of PTC patients has not increased significantly.^{2,3} Therefore, there is an urgent need to explore novel treatment strategies.

Many reports have revealed the regulatory mechanisms of non-coding RNAs (ncRNAs) involved in the progression of cancer.⁴⁻⁷ Circular RNAs (circRNAs) have been identified in various human cells, especially in tumor cells.^{8,9} For example, circRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of the miR-1324/FZD5/Wnt/β-catenin

Correspondence: Shuilong Zhang
Department of Thyroid Surgery, Shanxi Provincial People's Hospital, No. 29 Shuangtasi Street, Taiyuan, Shanxi 030012, People's Republic of China
Tel +86-0351-4960327
Email slzhang_shanxi@126.com

axis,¹⁰ circRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling,¹¹ while circRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.¹² In addition, it has been found that circRNAs are associated with multidrug resistance in tumors. For example, circRNA PVT1 modulates cell metastasis via the miR-181a-5p/NEK7 axis and cisplatin chemoresistance through miR-181a-5p-mediated autophagy in non-small cell lung cancer,¹³ and circRNA EIF6 sponges miR-144-3p to promote the cisplatin resistance of human thyroid carcinoma cells by autophagy regulation.¹⁴ However, circRNAs have rarely been studied in oncolytic viruses. It has been found that oncolytic viruses exhibit superior antitumor effects in cancer treatment.^{15,16} Therefore, it is of great significance to explore the relationship between circRNAs and oncolytic viruses.

In this work, we identified a novel circRNA (circRNA_103598) by analyzing the GEO database, and found the circRNA_103598 was upregulated in PTC tissues compared to non-tumor tissues. We also found that cell proliferation and oncolytic vaccinia virus (OVV)-mediated antitumor effects were promoted in PTC by regulating the circRNA_103598/miR-23a-3p/IL-6 axis. Thus, this study will provide new and important molecular targets for the diagnosis and treatment of PTC.

Materials and Methods

Clinical Samples and Cells

Tumor tissues and aired non-tumor (within 5 cm around tumors) tissues were collected from 100 PTC patients who received surgery at Shanxi Provincial People's Hospital from April 2015 to June 2019. All patients provided written informed consent. The Institutional Ethical Committee of Shanxi Provincial People's Hospital approved all aspects of the study.

PTC cell lines (BHP5-16, TPC-1, BHP2-7 and BCPAP) and normal human thyroid follicular epithelial cells (Nthy-ori-3-1) were purchased from the Cell Bank of Type Culture Collection (Shanghai City, China). All cells were cultured in DMEM (Gibco, USA) with 10% fetal bovine serum (FBS; Gibco, USA) and 1% penicillin (Sigma-Aldrich, St Louis, MO, USA)/streptomycin (Enpromise, Hangzhou, China). All cells were maintained at 37°C in a humidified chamber supplemented with 5% CO₂.

Cell Transfection

The shRNA against circRNA_103598 (sh-circRNA_103598: 5'-CACCGCACCCACGTTTCTCCTTGGACGAATCCAAGGAGAAACGTGGGTGC-3') was synthesized by GenePharma (Shanghai, China). BHP5-16 or TPC-1 cells in six-well plates were transfected with sh-circRNA_103598 or pcDNA3.1-IL-6 using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions.

RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Assay

Total RNA was isolated from PTC tumor tissues and cells based on the established protocol of TRIzol reagent (Thermo Fisher Scientific). The PrimeScript RT reagent kit (Takara Bio, Japan) was used to synthesize the cDNA, which was subjected to qRT-PCR in the presence of iQTM SYBR[®] Green Supermix (Bio-Rad Laboratories, Philadelphia, PA, USA). The results were calculated with the 2^{-ΔΔCt} method with normalization to GAPDH. The qRT-PCR primers used were as follows: circRNA_103598 forward: 5'-GAGATTATGGTGGCAGGGAATC-3', reverse: 5'-ACCATCCAGAATACCATGAAGG-3'; IL-6 forward: 5'-GAAAACACAGGGTCAGCAT-3', reverse: 5'-CAGCCACTGGTTT TTCTGCT-3'; GAPDH forward: 5'-ACAACCTTGGTATCGTGGAAAGG-3', reverse: 5'-GCCATCACGCCACAGTTTC-3'.

Cell Proliferation Assay

Cell proliferation was detected using the Cell Counting Kit-8 (CCK-8, ab228554; Abcam) assay according to the manufacturer's instructions. PTC cells were seeded into 96-well plates (5000 cells per well). After being cultivated in the incubator for 24, 48 and 72 h, cells were incubated with 10 μL CCK-8 reagent for 4 h. Finally, OD values were measured at 450 nm.

Nude Mouse Xenograft Assay

Ten female BALB/c nude mice (18–20 g, 4–5 weeks old) were obtained from the Shanghai Lab Animal Research Center (Shanghai, China). TPC-1 cells were injected subcutaneously into the posterior flank of BALB/c nude mice according to the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health. Animal protocols were approved by the Institutional Animal Care and Use Committee of Tongde Hospital of Zhejiang

Figure 1 Clinical significance of circRNA_103598 in indicating PTC progression. **(A)** circRNA_103598 was highly expressed in PTC tissues. **(B)** qRT-PCR assay of circRNA_103598 expression in PTC tissues and normal tissues. **(C)** Kaplan–Meier overall survival curves for 100 patients with PTC classified according to relative circRNA_103598 expression level. **(D)** Expression level of circRNA_103598 had potential clinical significance as a tumor biomarker by the receiver operating characteristics (ROC) curve. * $p < 0.05$.

Province. Tumor volumes were measured according to the formula: Volume (mm^3) = $1/2 \times \text{width}^2 \times \text{length}$.

IC₅₀ Assay

Cell viability was detected using the CCK-8 (ab228554, Abcam) assay according to the manufacturer's instructions. PTC cells were seeded into 96-well plates (5000 cells per well) and treated with vaccinia virus. After being cultivated in the incubator for 48 h, cells were incubated with 10 μL CCK-8 reagent for 4 h. Finally, OD values were measured at 450 nm.

Dual-Luciferase Reporter Assay

BHP5-16 or TPC-1 cells were plated in a six-well plate. Then, BHP5-16 or TPC-1 cells were co-transfected with reporter vectors and the indicated transfection plasmids for 48 h, and finally examined by the dual-luciferase reporter assay system (Promega) according to the manufacturer's instructions.

ELISA

IL-6 expression was detected using IL-6 ELISA kits (R&D Systems, Minnesota, USA) according to the manufacturer's instructions.

OVV Replication

BHP5-16 or TPC-1 cells were plated in 24-well plate, then treated with OVV at 1 MOI. After 6, 12, 24 and 48 h, cells and medium were collected and virus yield was examined by the TCID₅₀ assay in HEK293 cells according to the manufacturer's instructions.

Statistical Analysis

All data were collected from at least three independent biological replicates and were expressed as mean $\pm$ SD (standard deviation). Difference analysis was performed by the Student's *t*-test (comparison for two groups) using GraphPad Prism 7 software (GraphPad, La Jolla, CA, USA). Values of $p < 0.05$ were statistically significant.

Results

Clinical Significance of circRNA_103598 in Indicating PTC Progression

To begin with, the GEO data set (GSE93522) for circRNAs was analyzed from PTC tissues using the bioinformatics tool GEO2R, and circRNA_103598 was found to be highly expressed in PTC tissues (Figure 1A). In addition, circRNA_103598 was noticeably increased in PTC tissues ($n=100$) compared with the adjacent normal tissues (Figure 1B). As summarized in Table 1, high

Table 1 Correlation Between Clinicopathological Features and circRNA_103598 Expression in 100 Cases of PTC Tissues

Characteristics	circRNA_103598		p
	Low	High	
Age (years)			0.649
≤57	29	23	
>57	21	27	
Gender			0.523
Male	26	22	
Female	24	28	
Tumor size			<0.05
<5 cm	36	15	
≥5 cm	14	35	
TNM stage			<0.05
I–II	39	13	
III–IV	11	37	
Metastasis status			<0.05
No	37	12	
Yes	13	38	

expression of circRNA_103598 was associated with metastasis status, TNM stage and tumor size, while there was no significant relationship with gender and age. Moreover, Kaplan–Meier survival analysis revealed that the patients with high expression of circRNA_103598 had lower overall survival rates than those with low expression of circRNA_103598 (Figure 1C), and circRNA_103598 expression level had potential clinical significance as a tumor biomarker by the receiver operating characteristics (ROC) curve (Figure 1D). These results revealed that circRNA_103598 may play a role in the development of PTC.

CircRNA_103598 Knockdown Inhibited Cell Proliferation and OVV-Mediated Antitumor Effect in PTC

Owing to the higher expression of circRNA_103598 in BHP5-16 or TPC-1 cells, they were chosen for further functional analysis (Figure 2A). Applying the back-splice junction-specific shRNAs (sh-circRNA_103598), we successfully knocked down circRNA_103598 expression in BHP5-16 or TPC-1 cells (Figure 2B). As analyzed in cell proliferation and nude mouse xenograft assays, knockdown of circRNA_103598 remarkably suppressed the proliferation of PTC cells in vitro (Figure 2C) and in vivo (Figure 2D). In addition, the mice with knockdown of circRNA_103598 had

higher overall survival rates (Figure 2E). Furthermore, we found that knockdown of circRNA_103598 significantly decreased the IC₅₀ value of OVV in PTC (Figure 2F), suggesting that OVV exhibited a better antitumor effect in PTC cells with high circRNA_103598 expression. Thus, circRNA_103598 knockdown inhibited cell proliferation and the OVV-mediated antitumor effect in PTC.

CircRNA_103598 Promoted Cell Proliferation and OVV-Mediated Antitumor Effect in PTC via Sponging miR-23a-3p

Considering that circRNAs may sponge miRNAs, we investigated the candidate miRNAs of circRNA_103598. The online software miRBase and Circinteractome were used to predict the potential target of circRNA_103598. The putative binding sites between circRNA_103598 and miR-23a-3p and the mutant sequences of circRNA_103598 are described in Figure 3A. Thus, to confirm this prediction, the circRNA_103598 sequence with a miR-23a-3p binding site was inserted downstream of a luciferase gene to construct the pluc-circRNA_103598 vector for the dual-luciferase reporter assay. The results showed that luciferase activity of BHP5-16 or TPC-1 cells in the circRNA_103598-WT group was remarkably reduced by the introduction of miR-23a-3p, but not significant in the circRNA_103598-MUT group (Figure 3B). In addition, miR-23a-3p expression was significantly promoted by knockdown of circRNA_103598 in BHP5-16 or TPC-1 cells (Figure 3C). Furthermore, miR-23a-3p expression was noticeably decreased in PTC tissues and was negatively correlated with circRNA_103598 expression (Figure 3D and E). Functionally, the suppression of PTC cell proliferation and decreased IC₅₀ value of OVV caused by silencing circRNA_103598 could be reversed by transfecting miR-23a-3p inhibitor (Figure 3F and G), suggesting that circRNA_103598 promoted cell proliferation and OVV-mediated antitumor effect in PTC via sponging miR-23a-3p.

OVV-Mediated Antitumor Effect and Cell Proliferation Were Promoted in PTC by Regulating circRNA_103598/miR-23a-3p/IL-6 Axis

To elucidate the underlying network of miR-23a-3p in PTC, bioinformatics analysis was conducted to predict the potential target. The putative binding sites between IL-6 and miR-23a-3p are shown in Figure 4A. Subsequently, the

Figure 2 Knockdown of circRNA_103598 inhibited cell proliferation and OVV-mediated antitumor effect in PTC. **(A)** qRT-PCR analysis of circRNA_103598 expression in PTC cells. **(B)** The relative expression of circRNA_103598 in BHP5-16 and TPC-1 cells was detected by qRT-PCR assay after transfection with circRNA_103598. **(C)** Cell proliferation in BHP5-16 and TPC-1 cells was examined by CCK-8 assay. **(D)** circRNA_103598 knockdown decreased tumor volume in nude mice. **(E)** Mice with knockdown of circRNA_103598 had higher overall survival rates. **(F)** Knockdown of circRNA_103598 significantly decreased IC₅₀ values of OVV in PTC. **p* < 0.05.

dual-luciferase reporter assay indicated that luciferase activity of BHP5-16 or TPC-1 cells in the IL-6-WT group was remarkably reduced by the introduction of miR-23a-3p, but not significant in the IL-6-MUT group (Figure 4B). In addition, the qRT-PCR assay (Figure 4C) and ELISA (Figure 4D) revealed that IL-6 expression was remarkably decreased by transfecting miR-23a-3p mimic and was significantly increased by transfecting IL-6 in BHP5-16 or TPC-1 cells, and IL-6 expression was noticeably increased in PTC tissues (Figure 4E). IL-6 expression was negatively correlated with miR-23a-3p expression (Figure 4F) and showed a positive trend with circRNA_103598 expression (Figure 4G). Functionally, PTC cell proliferation (Figure 4H) and the IC₅₀ value of OVV (Figure 4I) in HP5-16 or TPC-1 cells could be suppressed by transfecting miR-23a-3p mimic, which was abrogated by transfecting IL-6. Moreover, the viral replication of OVV in HP5-16 or TPC-1 cells could be inhibited by transfecting miR-23a-3p

mimic, which was reversed by transfecting IL-6, suggesting that the OVV-mediated antitumor effect was promoted by regulating circRNA_103598/miR-23a-3p/IL-6 axis-mediated viral replication (Figure 4J).

Discussion

In the study of the molecular mechanisms of PTC, a lot of attention has been focused on miRNA, lncRNAs and protein-coding genes, whereas circRNAs, which act as cancer drivers, are not well illustrated in terms of their expression or potential molecular mechanism. PTC-involved circRNAs such as circRNA_102171,¹⁷ circBACH2¹⁸ and circZFR¹⁹ were indicated to enhance the invasion, migration and proliferation capacities of PTC cells. In this study, we first found that circRNA_103598 expression was remarkably increased in PTC tissues and cells. Knockdown of circRNA_103598 significantly suppressed PTC cell proliferation in vitro and in vivo. Moreover, high expression of circRNA_103598 was

Figure 3 Circular RNA_103598 promoted cell proliferation and OVV-mediated antitumor effect in PTC via sponging miR-23a-3p. **(A)** Potential targeting sites of circRNA_103598 and miR-23a-3p. **(B)** Relative luciferase activity—dual luciferase report assay. **(C)** Expression of miR-23a-3p was increased by silencing circRNA_103598 in BHP5-16 and TPC-1 cells. **(D)** qRT-PCR assay of miR-23a-3p expression in PTC tissues and normal tissues. **(E)** Expression of miR-23a-3p was negatively correlated with circRNA_103598 expression. Suppression of PTC cell proliferation **(F)** and decreased IC₅₀ values of OVV **(G)** caused by silencing circRNA_103598 could be reversed by transfecting miR-23a-3p inhibitor. **p*<0.05.

associated with metastasis status, TNM stage, tumor size and survival rates, implying that circRNA_103598 may act as a tumor biomarker in PTC.

A previous study revealed that circRNAs can act as ceRNAs (competing endogenous RNAs) of miRNAs to suppress the function of miRNA on target genes. For example, circRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630.⁹ Comprehensive circRNA profiling revealed the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis.²⁰ circC3P1 suppresses hepatocellular carcinoma growth and metastasis through the miR-4641/PCK1 pathway.²¹ In this study, the bioinformatics prediction combined with the dual-luciferase reporter assay revealed that circRNA_103598 acts as an endogenous sponge by binding miR-23a-3p. Moreover, we first found that IL-6 is a direct target for miR-23a-3p. Some studies have indicated that low expression of miR-

23a-3p and overexpression of IL-6 can contribute to tumor growth.^{22,23} Thus, cell proliferation was promoted in PTC by regulating the circRNA_103598/miR-23a-3p/IL-6 axis.

Earlier studies showed that overexpression of IL-6 enhances multidrug resistance in tumor treatment. For example, inhibition of IL-6 enhances chemosensitization in multi-drug-resistant human breast cancer cells.²⁴ Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer.²⁵ Another study showed inhibition of the IL-6–Stat3 pathway and reversal of Taxol and cisplatin resistance in drug-resistant ovarian cancer cell lines by a synthetic triterpenoid CDDO-Me.²⁶ Thus, exploration of a novel therapy strategy in PTC is urgently needed, and we found that the OVV-mediated antitumor effect was enhanced in PTC by regulating the circRNA_103598/miR-23a-3p/IL-6 axis. Therefore, this study may help to establish a therapeutic strategy for PTC according to circRNA_103598 expression.

Figure 4 OVV-mediated antitumor effect and cell proliferation were promoted in PTC by regulating the circRNA_103598/miR-23a-3p/IL-6 axis. **(A)** Potential targeting sites of IL-6 and miR-23a-3p. **(B)** Relative luciferase activity—dual luciferase report assay. IL-6 expression was detected by qRT-PCR assay **(C)** and ELISA **(D)**. **(E)** qRT-PCR assay of IL-6 expression in PTC tissues and normal tissues. **(F)** The expression of miR-23a-3p was negatively correlated with IL-6 expression. **(G)** Expression of circRNA_103598 showed a positive trend with circRNA_103598 expression. **(H)** Cell proliferation in BHP5-16 and TPC-1 cells was examined by CCK-8 assay. **(I)** IC₅₀ values of OVV in BHP5-16 and TPC-1 cells were detected by CCK-8 assay. **(J)** The viral replication of OVV in HP5-16 or TPC-1 cells was examined by TCID₅₀ assay. **p*<0.05.

Conclusions

Our study first revealed the high expression and oncogenic function of circRNA_103598 in PTC cells. Then, circRNA_103598 sponged miR-23a-3p to upregulate IL-6 expression, with the result that cell proliferation was promoted and the OVV-mediated antitumor effect was enhanced by strengthening the viral replication, providing new insights into future therapy for PTC.

Disclosure

The authors report no conflicts of interest in this work.

References

- Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. *J Cancer*. 2011;2:193–199. doi:10.7150/jca.2.193
- Oyer SL, Fritsch VA, Lentsch EJ. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients. *Ann Otol Rhinol Laryngol*. 2014;123(2):94–100.
- Ito Y, Kudo T, Kihara M, et al. Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years. *Endocr J*. 2012;59(10):895–901.
- Vidaurre S, Fitzpatrick C, Burzio VA, et al. Down-regulation of the antisense mitochondrial non-coding RNAs (ncRNAs) is a unique vulnerability of cancer cells and a potential target for cancer therapy. *J Biol Chem*. 2014;289(39):27182–27198.
- Chen EG, Zhang JS, Xu S, Zhu XJ, Hu HH. Long non-coding RNA DGCR5 is involved in the regulation of proliferation, migration and invasion of lung cancer by targeting miR-1180. *Am J Cancer Res*. 2017;7(7):1463–1475.
- Zhu Y, Li K, Yan L, He Y, Wang L, Sheng L. miR-223-3p promotes cell proliferation and invasion by targeting Arid1a in gastric cancer. *Acta Biochim Biophys Sin (Shanghai)*. 2020;52(2):150–159.
- Xie H, Ren X, Xin S, et al. Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. *Oncotarget*. 2016;7(18):26680–26691.
- Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. *Rna*. 2013;19(2):141–157.
- Zhang Y, Liu H, Li W, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630. *Aging*. 2017;9(6):1585–1594.
- Zhu Q, Lu G, Luo Z, et al. CircRNA circ_0067934 promotes tumor growth and metastasis in hepatocellular carcinoma through regulation of miR-1324/FZD5/Wnt/ β -catenin axis. *Biochem Biophys Res Commun*. 2018;497(2):626–632. doi:10.1016/j.bbrc.2018.02.119
- Qiu BQ, Zhang PF, Xiong D, et al. CircRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling. *J Cell Physiol*. 2019;234(7):11256–11264.
- Chen Q, Liu T, Bao Y, et al. CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. *Cancer Lett*. 2020;469:68–77.
- Yan L, Bai M, Xu J, et al. CircRNA PVT1 modulates cell metastasis via the miR-181a-5p/NEK7 axis and cisplatin chemoresistance through miR-181a-5p-mediated autophagy in non-small cell lung. *RSC Adv*. 2019;9(9):42324–42334.
- Liu F, Zhang J, Qin L, et al. Circular RNA EIF6 (Hsa_circ_0060060) sponges miR-144-3p to promote the cisplatin-resistance of human thyroid carcinoma cells by autophagy regulation. *Aging*. 2018;10(12):3806–3820.
- Lin SF, Price DL, Chen CH, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. *J Clin Endocrinol Metab*. 2008;93(11):4403–4407.
- Garber K. China approves world's first oncolytic virus therapy for cancer treatment. *J Natl Cancer Inst*. 2006;98(5):298–300.
- Bi W, Huang J, Nie C, et al. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of beta-catenin pathway. *J Exp Clin Cancer Res*. 2018;37(1):275.
- Cai X, Zhao Z, Dong J, et al. Circular RNA circBACH2 plays a role in papillary thyroid carcinoma by sponging miR-139-5p and regulating LMO4 expression. *Cell Death Dis*. 2019;10(3):184.
- Wei H, Pan L, Tao D, Circular LR. RNA circZFR contributes to papillary thyroid cancer cell proliferation and invasion by sponging miR-1261 and facilitating C8orf4 expression. *Biochem Biophys Res Commun*. 2018;503(1):56–61.
- Wang H, Xiao Y, Wu L, Ma D. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis. *Int J Oncol*. 2018;52(3):743–754.
- Zhong L, Wang Y, Cheng Y, et al. Circular RNA circC3P1 suppresses hepatocellular carcinoma growth and metastasis through miR-4641/PCK1 pathway. *Biochem Biophys Res Commun*. 2018;499(4):1044–1049.
- Chen F, Qi S, Zhang X, Wu J, Yang X, Wang R. miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2. *Pathol Res Pract*. 2019;215(4):660–667.
- Wehbe H, Henson R, Meng F, Mize-Berge J, Lang M, Patel T. Overexpression of IL-6 can contribute to tumor growth by altered promoter methylation and gene expression in human cholangiocarcinoma. *Proc Amer Assoc Cancer Res*. 2006;47.
- Yang W, Chen L-P, Huang R, Huang R-P. Inhibition of IL-6 and IL-8 enhances chemosensitization in multidrug resistant human breast cancer cells. *Proc Amer Assoc Cancer Res*. 2005;46:1199.
- Xu H, Zhou Y, Li W, et al. Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. *Oncol Lett*. 2018;15(6):9142–9150.
- Duan Z, Ames R, Ryan M, Seiden M. Inhibition of the IL-6-Stat3 pathway and reversal of Taxol and cisplatin resistance in drug resistant ovarian cancer cell lines by a synthetic triterpenoid CDDO-Me. *Am Assoc Cancer Res*. 2007;67:2394.

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>

Dovepress

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.